US Pharma MarketingAt ASCO 2026, a ‘paradigm shift’ for a rare gut cancer looms
For patients with a rare cancer that arises in the gut wall, standard treatment hasn’t changed in the last 20 years. For patients with a rare cancer that arises in the gut wall, standard treatment hasn’t changed in the last 20 years. At the American Society of Clinical Oncology meeting in Chicago, GSK shared a first look at its attempt to change that. Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small Molecule Research &…
For patients with a rare cancer that arises in the gut wall, standard treatment hasn’t changed in the last 20 years. At the American Society of Clinical Oncology meeting in Chicago, GSK shared a first look at its attempt to change that.
Source: FierceBiotech